Payment overview · 2025
General Payments
$602.53
39 reported records · 10 companies
Healthcare provider profile · identity verified
John Robert Behm, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · OWOSSO, MI · NPI 1528012366
Verified facts
What the public records show
CMS Open Payments records show John Robert Behm, D.O. received $602.53 in general payments during 2025 across 39 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $187.12 | 31.1% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $181.25 | 30.1% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.90 | 7.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.31 | 6.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.74 | 6.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.98 | 5.6% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.92 | 4.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.38 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.96 | 3.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.97 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $602.53 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $187.12 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $150.52 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.90 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $33.35 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 542 | 135 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 453 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 302 | 92 |
| Morphine Sulfate Er | Morphine Sulfate | 264 | 21 |
| Methadone Hcl | Methadone Hcl | 225 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 224 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 65 |
| Metformin Hcl | Metformin Hcl | 217 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 86 |
| Gabapentin | Gabapentin | 184 | 62 |
| Omeprazole | Omeprazole | 170 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 56 |
| Lisinopril | Lisinopril | 160 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 156 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 41 |
| Meloxicam | Meloxicam | 139 | 73 |
| Bumetanide | Bumetanide | 132 | 43 |
| Ezetimibe | Ezetimibe | 132 | 34 |
| Glimepiride | Glimepiride | 125 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 43 |
| Eliquis | Apixaban | 118 | 26 |
| Lorazepam | Lorazepam | 113 | 22 |
| Losartan Potassium | Losartan Potassium | 112 | 32 |
| Spironolactone | Spironolactone | 110 | 33 |
| Trazodone Hcl | Trazodone Hcl | 109 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 106 | 36 |
| Tramadol Hcl | Tramadol Hcl | 106 | 19 |
| Celecoxib | Celecoxib | 103 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 36 |
| Morphine Sulfate | Morphine Sulfate | 102 | 11 |
| Metformin Hcl Er | Metformin Hcl | 101 | 28 |
| Potassium Chloride | Potassium Chloride | 98 | 32 |
| Sertraline Hcl | Sertraline Hcl | 94 | 19 |
| Clonazepam | Clonazepam | 91 | 13 |
| Pregabalin | Pregabalin | 89 | 36 |
| Montelukast Sodium | Montelukast Sodium | 88 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 25 |
| Carvedilol | Carvedilol | 85 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 33 |
| Allopurinol | Allopurinol | 79 | 28 |
| Alprazolam | Alprazolam | 78 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 78 | 19 |
| Jardiance | Empagliflozin | 78 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 36 |
| Furosemide | Furosemide | 66 | 28 |
| Donepezil Hcl | Donepezil Hcl | 65 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 20 |
| Mirtazapine | Mirtazapine | 61 | 23 |
| Aripiprazole | Aripiprazole | 59 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 28 |
| Diazepam | Diazepam | 53 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 19 |
| Ondansetron Odt | Ondansetron | 51 | 23 |
| Memantine Hcl | Memantine Hcl | 50 | 16 |
| Simvastatin | Simvastatin | 50 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 47 | 13 |
| Prednisone | Prednisone | 46 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 13 |
| Atenolol | Atenolol | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 12 |
| Ketoconazole | Ketoconazole | 41 | 21 |
| Risperidone | Risperidone | 41 | suppressed |
| Fentanyl | Fentanyl | 40 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 37 |
| Famotidine | Famotidine | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 30 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 11 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Olanzapine | Olanzapine | 31 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | 16 |
| Hydromorphone Hcl | Hydromorphone Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Ozempic | Semaglutide | 28 | 12 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 28 | suppressed |
| Sulindac | Sulindac | 28 | 11 |
| Acyclovir | Acyclovir | 27 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Nystatin | Nystatin | 26 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | 12 |
| Telmisartan | Telmisartan | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Phenytoin | Phenytoin | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Tri-Mili | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $602.53 · 39 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, ARISTADA, Auvelity, CAPLYTA, FARXIGA, LYBALVI, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error